Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

NCT01338857 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT01338857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01338857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2011
Completion date
March 31, 2013
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis1 (nf1), recurrent or progressive low-grade glioma, recurrent or progressive optic pathway gliomas (opg)